

IT&E INTERNATIONAL GROUP  
 Form 8-K  
 September 19, 2006

UNITED STATES  
 SECURITIES AND EXCHANGE COMMISSION  
 WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
 PURSUANT TO SECTION 13 OR 15(d)  
 OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) September 15, 2006

IT&E International Group, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-50095	20-4354185
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4 California Avenue, Framingham, Massachusetts		01701
(Address of principal executive offices)	Registrant's telephone number, including area code <u>508-416-2600</u>	(Zip Code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers**

(b) On September 15, 2006, Kelly Alberts resigned from our board of directors (the Board) and as our President. Mr. Alberts' resignations did not relate to any disagreements with us on any matter related to our operations, policies or practices. Mr. Alberts will continue on in a more limited role, assisting us on a part-time basis. We have not yet identified a replacement for Mr. Alberts on our Board.

(c) Effective September 15, 2006, Dr. George Van Lear, 65, was appointed as Interim President of the IT&E International division of our Company.

From 2000 to 2005, Dr. Van Lear served as Chair and President of aaiPharma's research division, where he led the internal Research and Development functions. Prior to that, from 1999 to 2000, Dr. Van Lear served as President and Chief Operating Officer of Senetek, PLC, a biotechnology firm. Dr. Van Lear started his career at Lederle Laboratories from 1968-1984 where he was Group Leader in Drug Metabolism and Mass Spectroscopy and then later as Head of the Analytical Services Department. From 1984 to 1999, Dr. Van Lear held a number of executive positions at Applied Analytical Industries, Glaxo, Innapharma and DPT Laboratories. Dr. Van Lear earned his undergraduate degree in Chemistry from Millikin University, a Ph.D. in Organic Chemistry from the University of Utah as well as two postdoctoral fellowships at

## Edgar Filing: IT&E INTERNATIONAL GROUP - Form 8-K

University of Illinois and Purdue University.

Dr. Van Lear's employment will be at-will. He will receive a salary of \$16,667 per month. Dr. Van Lear will also be eligible to receive stock awards under our 2005 Equity Incentive Plan at the sole discretion of our Board.

---

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IT&E International Group, Inc.

By: /s/ Dr. Philip T. Lavin  
Dr. Philip T. Lavin  
Chief Executive Officer

Dated: September 19, 2006